TWThomas Werfel

Thomas Werfel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Werfel has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dupilumab in Atopic Dermatitis – Rate of Poor Responders and Potential Risk Factors from the TREATgermany Registry

    by Annice Heratizadeh, Joëlle Naim, Barbara Kind, Katharina Loennecke, Sascha Fischer, Tatjana Honstein, Stephan Traidl, Eva Moennig, Thomas Birkner, Inken Harder, et al.

    A distinct proportion of patients with atopic dermatitis and dupilumab treatment does not reach the primary endpoint of an eczema area severity index (EASI)-75 or investigator global assessment 0/1 after 16 weeks. Little is known about poor responders to dupilumab in real life scenarios. The study objective was to identify the percentage and characteristics of patients with insufficient treatment response to dupilumab based on “TREATgermany” registry data from dermatological routine care. Between 06/2016 and 12/2024, 476 patients matched the study criteria. In total, 4% of patients (n=19) were identified as dupilumab poor responders, i.e. reduction in EASI ≤40% at the 1st follow-up visit after 8 to 20 weeks and a consecutive 2nd follow-up visit up to 52 weeks of treatment. 44% (n=209) were classified as stable responders, i.e. decrease in EASI≥75% at both follow-up visits. Poor responders were significantly more often male, more frequently exhibited smoking, arterial hypertension and a higher body mass index. This TREATgermany data analysis demonstrates a proportion of 4% dupilumab poor responders within the first year of treatment. Male sex, smoking, arterial hypertension and increased body mass index were identified as potential risk factors. Further translational research is needed to confirm these clinical findings.

  • Open Access

    Real-world Effectiveness and Safety of Lebrikizumab in Atopic Dermatitis: A TREATgermany Analysis

    by Barbara Kind, Christina Pham, Luise Heinrich, Tatjana Honstein, Annice Heratizadeh, Inken Harder, Dora Stölzl, Petra Staubach-Renz, Thomas Schaefer, Susanne Abraham, et al.

    Atopic dermatitis (AD) is driven by type 2 inflammation, with interleukin-13 (IL-13) as one of the central operators. Lebrikizumab is a monoclonal antibody that inhibits IL-13 signalling. Adult patients with moderate-to-severe AD who received lebrikizumab in the TREATgermany registry until 12/2024 were selected, and patient characteristics as well as effectiveness and safety outcomes after 1, 3 and 6 months were evaluated. A total of 108 patients were initiated on lebrikizumab, with 80 having follow-up data available for this analysis (“registry cohort”). Forty-one patients were switched to lebrikizumab without a “washout period” from another advanced systemic therapy (“switchers”). The mean Eczema Area and Severity Index (EASI) decreased from 14.8 at baseline to 5.6 and 3.0 at month 3 and month 6 and was comparable between switchers and nonswitchers. Clinically meaningful improvements were also seen across all patient reported outcomes (PROs) equally in both groups, e.g. a decrease of the mean peak pruritus numeric rating scale (PP-NRS) from 6.6 to 3.8 and 3.4 and the Dermatology Life Quality Index (DLQI) from 11.9 to 4.9 and 4.8. Overall, adverse events (AEs) were reported for 26.6% of patients within the first 3. The most frequently reported AE was conjunctivitis or other ocular complications, reported in 13 patients (20.3%). 32 patients (40%) had an initial EASI≥16 and were comparable to patients in lebrikizumab phase 3 studies. In this “trial-like” cohort, EASI-75 and EASI-90 response rates were 60% and 26.7% at month 3 and 70% and 50% at month 6. Lebrikizumab shows effectiveness in routine care well comparable to observations made in randomized controlled trials.

  • Open Access

    Patient treatment needs in atopic dermatitis: A real‐world cohort study

    by Kristina Ludemann, Stephan Traidl, Angela Cornelius, Joëlle Naim, Annice Heratizadeh, Tatjana Honstein, Barbara Kind, Luise Heinrich, Inken Harder, Dora Stölzl, et al.

    Background: Atopic dermatitis (AD) substantially affects quality of life, yet standardized severity measures may not capture patient‐centred priorities, making systematic needs assessment essential for personalized care. Objectives: This study aimed to systematically assess and rank treatment needs in adults with moderate to severe AD, identify patient subgroups with distinct need profiles and evaluate how well these needs were met after 2 years of specialized dermatological care. Methods: In this prospective observational study from the TREATgermany registry, 697 adults with moderate to severe AD completed the validated Patient Benefit Index (PBI) at baseline (T1) and at 2‐year follow‐up (T2), capturing treatment goal importance and achievement. Subgroup analyses were performed based on age, sex, educational status and age at AD onset. Associations between clinical measures and perceived benefit were analysed. Results: The most frequently prioritized treatment goals were being free of itching (97.8% high agreement), regaining control of the disease (95.3%) and relief from skin burning (92.0%). The importance of itch reduction was not correlated with baseline pruritus intensity, and perceived benefit was more closely linked to relative clinical improvement than to absolute disease severity. Beyond these shared priorities, treatment needs varied across subgroups: older patients valued treatment safety and reduced dependence on medical care, women emphasized psychosocial and appearance‐related goals, individuals with lower educational status highlighted financial concerns and patients with adult‐onset AD prioritized diagnostic certainty and disease control. After 2 years, 96.6% of patients reported meaningful treatment benefit. Patient‐reported outcomes (POEM) were more strongly associated with perceived benefit than physician‐assessed measures (oSCORAD, EASI). Conclusion: Patient treatment needs in AD vary by demographic and clinical factors, with pruritus consistently rated as the highest priority. Patient‐reported outcomes align more closely with perceived benefit than physician assessments, underscoring the value of systematic needs assessments to guide individualized treatment decisions and shared decision‐making.

  • Open Access

    A Real-world Meta-analysis Study of Disease Severity in European Patients Who Received Baricitinib for Atopic Dermatitis: Data from BioDay, SCRATCH and TREATgermany

    by Celeste Boesjes, Marjolein de Bruin-Weller, Nicolaas P. A. Zuithoff, Said el Bouhaddani, Inge Haeck, Marijke Kamsteeg, Marie-Louise Schuttelaar, Luca Le Treust, Nick Denholm, Ahmet Akkoc, et al.

    Clinical trials have demonstrated the effectiveness of baricitinib, an oral selective Janus kinase 1/2 inhibitor, for patients with moderate-severe atopic dermatitis, but data from real-world practice are limited. This non-interventional cohort study evaluated clinician- and patient-reported disease severity over 16 weeks using 3 national atopic dermatitis registries: BioDay (Netherlands), SCRATCH (Denmark) and TREATgermany (Germany). Absolute scores for Eczema Area and Severity Index (EASI) and itch Numerical Rating Scale (Itch-NRS) were assessed at baseline and follow-up (Week 13/16) for each registry and for the overall pooled cohort. Descriptive analyses, generalized linear mixed modelling and meta-analysis approaches were applied to complete-case and multiply-imputeddatasets. In total, 264 patients (89 BioDay, 117 SCRATCH, 58 TREATgermany) were included. Results showed improvements in EASI, with58%, 68% and 62% achieving EASI≤7 at Week 13/16 in BioDay, SCRATCH and TREATgermany, respectively. In the pooled cohort, the proportion was 62% (95% CI: 50–73%). The pooled mean EASI change was -7.8 [14.4,–1.1]. Effectiveness was generally observed in both biologic-naïve and -experienced patients. Notable heterogeneity was observed, particularly for Itch-NRS, with the proportion achieving NRS≤4 ranging from 20% (BioDay) to 71% (TREATgermany). These real-world findings support the effectiveness of baricitinib while also highlighting variability in patient outcomes.

  • Open Access

    Patch Test Results With the European Baseline Series, 2021/2022—Joint European Results of the ESSCA A and the EBS B Working Groups of the ESCD , and the GEIDAC C

    by Wolfgang Uter, S. Mark Wilkinson, Olivier Aerts, Andrea Bauer, Leopoldo Borrego, Richard Brans, Timo Buhl, Heinrich Dickel, Aleksandra Dugonik, Francesca Larese Filon, et al.

    Background: Patch test results obtained with the European Baseline Series (EBS) in its current version serve both contact allergy surveillance and (re‐)assessing the diagnostic value of EBS allergens. Objectives: To present results of current EBS patch testing, obtained in 59 departments in 14 European countries during 2021 and 2022. Methods: Anonymised or pseudonymised individual data, and partly aggregated results, on demographic/clinical characteristics and patch test results with the EBS were prospectively collected, centrally pooled, and retrospectively analysed. Results: In 2021 and 2022, 18 832 patients were patch tested with the EBS. Sensitization to nickel remained most common (18.85 (18.29–19.43)% positivity (95% confidence interval)). Fragrance mix I and Myroxylon pereirae resin yielded very similar results with 6.39 (6.04–6.76)% and 6.5 (6.15–6.87)% positivity, respectively. Concerning preservatives, methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) 0.02% aq. yielded 5.52 (5.11–5.96)% and MI 0.2% aq. yielded 5.28 (4.94–5.64)% positives. Testing formaldehyde 2% aq. identified almost one percentage point more positive reactions than 1% aq. (2.05 (1.81–2.32)% vs. 1.22 (0.99–1.48)). Positive reactions to the recently added allergens were most frequently seen to propolis (5.47 (5.12–5.84)%) and 2‐hydroxyethyl methacrylate (3.63 (3.32–3.96)%). Conclusions: Compared to the previous reporting period, surveillance results with the EBS were mostly stable. The results regarding Quaternium 15 (0.4 (0.29–0.53)% positives) justified its exclusion from the 2023 EBS version.


  • Hauterkrankungen (ohne Allergien)

    by Stephan Traidl, Annice Heratizadeh, Thomas Werfel

  • Open Access

    Large Eczema Area and Severity Index response at 2-year follow-up of patients treated with dupilumab in routine care of atopic dermatitis: results from the national registry TREATgermany

    by Luise Heinrich, Thomas Birkner, Susanne Abraham, Sascha Gerdes, Tatjana Honstein, Sigrid Müller, Matthias Augustin, Inken Harder, Thomas Schaefer, Andreas Pinter, et al.

    The TREATgermany registry was set up in 2016. We provide results on long-term dupilumab therapy in adults with moderate and severe atopic dermatitis (AD) in a routine care setting. The analysis cohort of 294 patients is one of the largest cohorts with 2-year follow-up data on treatment effects of dupilumab obtained from an AD registry to date. We report the Harmonising Outcome Measures for Eczema (HOME) core outcome set. The Eczema Area Severity Index (EASI) 75 and EASI 90 response rates for patients on treatment at month 24 were 78.8% and 51.2%, respectively.

  • Open Access

    Implementing Federated Analysis Using DataSHIELD in the DREAM TO TREAT Atopic Dermatitis Registries Collaboration

    by Niels Steen Krogh, David Prieto-Merino, Bolaji Coker, Thomas Birkner, Ahmet Akkoc, Elizaveta Gribaleva, Ida Vittrup Nielsen, Anne Grete Frostrup, Maria Oberländer Christensen, Simon Francis Thomsen, et al.


  • Author Response to Poto et al. (2025): The Intriguing Role of Short‐Form TSLP by Zeitvogel et al.

    by Katinka Döhner, Jana Zeitvogel, Ilona Klug, Timmy Richardo, Beate Sodeik, Thomas Werfel